ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid arthritis (RA)"

  • Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting

    Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications

    Raj Vachhani1, Lang Chen 1, Ronan O'Beirne 2, Joshua Melnick 3, Eric Ruderman 4, Jeffrey Curtis 1 and Maria Danila 2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3University of Alabama at Birmingham, Birmimgham, AL, 4Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL

    Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…
  • Abstract Number: 2309 • 2019 ACR/ARP Annual Meeting

    Clinical Study of Peripheral Blood Lymphocyte Subsets in Patients with Rheumatoid Arthritis Complicated with Osteoporosis

    Ting Cheng1, Sheng-xiao Zhang 2, Xiao-qing Liu 1, Jia Wang 1, Chong Gao 3 and Xiao-feng Li 1, 1The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), 2The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), 3Brigham and Women’s Hospital, Harvard Medical School, Boston

    Background/Purpose: Rheumatoid arthritis(RA) is an autoimmune disease mainly manifested by aggressive polyarthritis.The incidence of osteoporosis(OP) has risen and the risk of fracture has further increased…
  • Abstract Number: 2329 • 2019 ACR/ARP Annual Meeting

    Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium

    Rabia Iqbal1, Elizabeth Park 2, Seitetsu Lee 3, Isabelle Amigues 4, Christopher Depender 2, Afshin Zartoshti 2, Jon Giles 5, Sabahat Bokhari 6 and Joan Bathon 5, 1Division on Rheumatology, Columbia University, Philadelphia, PA, 2Division on Rheumatology, Columbia University, New York, NY, 3Division of Cardiology, Columbia University, New York, NY, 4National Jewish Health, Denver, CO, 5Division of Rheumatology, Columbia University, New York, NY, 6Division of Cardiology and Nuclear Cardiology Laboratory, Columbia University, New York, NY

    Background/Purpose: The risk of developing heart failure (HF) in RA patients as compared with non-RA subjects is significantly higher even when adjusted for traditional cardiovascular…
  • Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting

    Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis

    Jeffrey Curtis1, Fenglong Xie 2, Cynthia Crowson 3, Brent Mabey 4, Darl Flake 4, Richard Bamford 4, Cheryl Chin 4, Eric Sasso 5, Elena Hitraya 5, Alexander Gutin 4 and Jerry Lanchbury 4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3Mayo Clinic Rochester, Rochester, 4Myriad Genetics, Inc, South San Francisco, CA, 5Crescendo Bioscience, South San Francisco, CA

    Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…
  • Abstract Number: 2375 • 2019 ACR/ARP Annual Meeting

    Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports

    Hiroaki Matsuno 1, Tatsuya Atsumi 2, Shuji Takei 3, Naoto Tamura 4, Masayoshi Harigai 5, Takao Fujii 6, Shigeki Momohara 7, Yuko Takahashi 8, Nobuhiro Narii 8, Naoto Tsujimoto 8, Atsushi Nishikawa 8, Taeko Ishii8, Kazuhiko Yamamoto 9, Masataka Kuwana 10 and Michiaki Takagi 11, 1Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 2Hokkaido University, Sapporo, Japan, 3Kagoshima University, Kagoshima, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 5Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 6Wakayama Medical University, Wakayama, Japan, 7Hakkeikai Incorporated Medical Institution, Shizuoka, Japan, 8Eli Lilly Japan K.K., Kobe, Japan, 9Riken Center for Integrative Medical Sciences, Kanagawa, Japan, 10Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, 11Yamagata University Faculty of Medicine, Yamagata-shi, Japan

    Background/Purpose: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/ and JAK 2, is used to treat moderately to severely active RA…
  • Abstract Number: 2407 • 2019 ACR/ARP Annual Meeting

    The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis

    Kunihiro Yamaoka1, Yoshiya Tanaka 2, Hideto Kameda 3, Barbara Hendrickson 4, Sebastian Meerwein 5, Ying Zhang 4 and Tsutomu Takeuchi 6, 1Kitasato University School of Medicine, Kanagawa, Japan, Kanagawa, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Toho University, Tokyo, Japan, Tokyo, Japan, 4AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 5AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 6Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 versus JAK2, JAK3, and TYK2, and is currently being assessed…
  • Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting

    Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use

    Michael George1, Joshua Baker 2, Lang Chen 3, Qufei Wu 2, Fenglong Xie 4, Huifeng Yun 3 and Jeffrey Curtis 3, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham, Birmingham

    Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…
  • Abstract Number: 51 • 2019 ACR/ARP Annual Meeting

    Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)

    Yuki Ishikawa1, Motomu Hashimoto 2, Katsunori Ikari 3, Koichiro Ohmura 4, Masao Tanaka 4, Hiromu Ito 4, Atsuo Taniguchi 3, Hisashi Yamanaka 3, Tsuneyo Mimori 4 and Chikashi Terao 5, 1Joslin Diabes Center, Boston, MA, 2Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3Tokyo Women’s Medical University, Tokyo, Japan, 4Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5RIKEN, Tokyo, Japan

    Background/Purpose: In rheumatoid arthritis (RA), cigarette smoking affects both rheumatoid factor (RF) and anti-citrullinated cyclic peptide/protein antibody (ACPA) production, but its association in relation to…
  • Abstract Number: 184 • 2019 ACR/ARP Annual Meeting

    No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA

    Yinzhu Jin 1, Sarah Chen 2, Jun Liu 1, Rishi Desai 3 and Seoyoung C. Kim1, 1Brigham and Women’s Hospital and Harvard Medical School, Boston, 2Brigham and Women's Hospital and Harvard Medical School, Boston, 3Brigham and Women's hospital, Boston

    Background/Purpose: Some previously published studies suggest that patients with rheumatoid arthritis (RA) are at an increased risk of developing diabetes mellitus. We examined the risk…
  • Abstract Number: 260 • 2019 ACR/ARP Annual Meeting

    Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014

    Shraddha Jatwani1, Karan Jatwani 2 and Karan Chugh 1, 1St. Vincent Evansville, Evansville, 2Mount Sinai West - St Luke’s Hospital, New York

    Background/Purpose: Venous thromboembolism (VTE) is a major health problem and can be potentially fatal when complicated by lethal pulmonary embolism (PE). Previous hospital-based studies have…
  • Abstract Number: 443 • 2019 ACR/ARP Annual Meeting

    Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis

    Irazú Contreras-Yáñez 1, Pilar Lavielle 2, Patricia Clark 3 and Virginia Pascual-Ramos1, 1Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, 2Clinical Epidemiology Unit, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico City, Mexico, 3Head of the Clinical Epidemiology Unit, Hospital Infantil de México Federico Gómez-Facultad de Medicina UNAM, Mexico City, Mexico

    Background/Purpose: Treatment recommendations directed to rheumatoid arthritis patients (RA) may be more easily adopted if they are patient-centered. The adoption of health behaviors is associated…
  • Abstract Number: 468 • 2019 ACR/ARP Annual Meeting

    Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C – Reactive Protein Levels with the Body’s Inflammatory Status

    Shumaila Iqbal1, Linda Burns 2, Joseph Grisanti 2 and Cassandra Zhi 3, 1University at Buffalo, Sisters of Charity Hospital, Buffalo, 2Buffalo Rheumatology and Medicine, Buffalo, 3Dexel University College of Medicine, Philadelphia, PA

    Background/Purpose: Current literature evaluating the effect of high Body Mass Index (BMI) on the disease activity of patients with rheumatoid arthritis (RA) is mixed as…
  • Abstract Number: 505 • 2019 ACR/ARP Annual Meeting

    Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission

    Takeshi Suzuki1, Marina Uchida 2, Shoshi Shinagawa 2, Machiko Mizushima 3, Takayasu Ando 3, Yutaka Gotou 3, Tomohiko Shibata 2 and Kimito Kawahata 4, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan, 3Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, 4Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan

    Background/Purpose: It has been recommended that tapering csDMARDs should be considered if a patient is in persistent remission. However, methods for tapering csDMARDs, including MTX,…
  • Abstract Number: 628 • 2019 ACR/ARP Annual Meeting

    Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis

    Alexis Ogdie1, Sofia Pedro 2 and Kaleb Michaud 3, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…
  • Abstract Number: 923 • 2019 ACR/ARP Annual Meeting

    First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?

    Gulsen Ozen1, Sofia Pedro 2, Rebecca Schumacher 2, Teresa Simon 3 and Kaleb Michaud 1, 1University of Nebraska Medical Center, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Bristol-Myers Squibb*, Princeton, NJ

    Background/Purpose: Chronic inflammation is linked to increased risk of cardiovascular disease (CVD) in RA that may manifest as venous thromboembolism (VTE) or atherosclerotic CVD (ASCVD).…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology